Cidofovir: Clinical experience and future perspectives on an acyclic nucleoside phosphonate analog of cytosine in the treatment of refractory and premalignant HPV-associated anal lesions

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 8, 2009, Pages 1343-1352

  Coremans, Georges ^a   Snoeck, Robert ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

AIN; Antiviral activity; Apoptosis; Cidofovir; Condylomata acuminata; HPMPC; HPV associated anogenital lesions; Nephrotoxicity; Phosphorylated metabolites

Indexed keywords

ACYCLIC NUCLEOSIDE; ALPHA2 INTERFERON; CIDOFOVIR; CYTOSINE; FLUOROURACIL; IMIQUIMOD; PHOSPHONIC ACID DERIVATIVE; PHOTOSENSITIZING AGENT; ZIDOVUDINE;

ANAL LESION; ANTIVIRAL ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; BOWEN DISEASE; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LESIONS AND DEFECTS; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NEOPLASM; NEPHROTOXICITY; NONHUMAN; PENIS DISEASE; PRECANCER; PROTEINURIA; RECURRENT INFECTION; REVIEW; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; VIRUS INFECTION; VULVA DISEASE;

ANTIVIRAL AGENTS; ANUS NEOPLASMS; CYTOSINE; HUMANS; PAPILLOMAVIRIDAE; PHOSPHONIC ACIDS; PRECANCEROUS CONDITIONS; TUMOR VIRUS INFECTIONS;

EID: 67649723449     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902960154     Document Type: Review

References (63)

1. Stone KM. Human papillomavirus infection and genital warts. Update on epidemiology and treatment. Clin Infect Dis 1995;20:S91-7
2. Schmook T, Nindl I, Ulrich C, et al. Viral warts in organ transplant recipients: new aspects in therapy. Br J Dermatol 2003;149 (Suppl66):20-24 (Pubitemid 38064509)
3. Bobrowska K, Kaminski P, Cyganek A, et al. Multiple neoplastic lesions of the lower genital tract in a human papilloma virus-infected kidney-pancreas allograft recipient: a case report. Transplant Proc 2005;37:2093-2095 (Pubitemid 40956382)
4. Patel HS, Silver AR, Northover JM. Anal cancer in renal transplant patients. Int J Colorectal Dis 2005;22:1-5
5. Hyckel P, Schleier P, Meerbach A, et al. The therapy of virus-associated epithelial tumors of the face and the lips in organ transplant recipients. Med Microbiol Immunol 2003;192:171-176 (Pubitemid 37100664)
6. Schneider A, Kinsky LA. Natural history and epidemiological features of genital HPV infection. IARC Sc Publ 1992;119:25-52
7. Kiviat NB. Human papillomavirus and hepatitis viral infections in human immunodeficiency virus-infected persons. In: De Vita VT, Hellman S, Rosenberg SA editors. AIDS Etiology, Diagnosis, Treatment and Prevention, 4th edn. Lippincott-Raven, Philadelphia, 1997. p. 281-294
8. Pruvost C, Penso-Assathiany D, Bachot N, et al. Risk factors for cutaneous wart onset in transplant recipients. Ann Dermatol Venereol 2002;129:291-293 (Pubitemid 34296902)
9. Ramsay HM, Fryer AA, Reece S, et al. Clinical risk factors associated with non melanoma skin cancer in renal transplant recipients. Am J Kidney Dis 2000;36:167-176 (Pubitemid 30432579)
10. Rudlinger R, Smith IW, Bunney MH, Hunter JA. Human papillomavirus infections in a group of renal transplant recipients. Br J Dermatol 1986;115:681-692 (Pubitemid 17181893)
11. Soler C, Chardonnet Y, Allibert P, et al. Detection of mucosal human papillomavirus types 6/11 in cutaneous lesions from transplant recipients. J Invest Dermatol 1993; 101: 286-291 (Pubitemid 23269898)
12. Van Ranst M, Kaplan JB, Burk RD. Phylogenetic classification of human papillomaviruses: correlation with clinical manifestations. J Gen Virol 1992;73:2653-2660
13. Laytragoon-Lewin N, Nilsson PJ, Castro J, et al. Human papillomavirus (HPV), DNA aberrations and cell cycle progression in anal squamous carcinoma patients. Anticancer Res 2007;27:4473-4479
14. Kiviat NB, Critchlow CW, Holmes KK, et al. Association of anal dysplasia and human papillomavirus with immunosuppression and HIV infection among homosexual men. AIDS 1993;7(1): 43-49 (Pubitemid 23069031)
15. Surawicz CM, Critchlow C, Sayer J, et al. High grade anal dysplasia in visually normal mucosa in homosexual men: seven cases. Am J Gastroenterol 1995;90:1776-1778
16. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the economic annual burden to preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmaeconomics 2005;23(11):1107-1122 (Pubitemid 41633402)
17. Garden JM, O'banion MK, Shelnitz LS, et al. Papillomavirus in the vapor of carbon dioxide laser-treated verrucae. JAMA 1988;259:1199-1202 (Pubitemid 18058832)
18. Garden JM, O'banion MK, Bakus AD, Olson C. Viral disease transmitted by laser-generated plume (aerosol). Arch Dermatol 2002;138:1303-1307
19. Sawchuk WS, Felten RP. Infectious papillomavirus in the vapor of warts treated with carbon dioxide laser or electrocoagulation: detection and protection. J Am Acad Dermatol 1989;21:41-49 (Pubitemid 19171464)
20. Gloster HM Jr, Roenigk RK. Risk of acquiring human papillomavirus from the plume produced by the carbon dioxide laser in the treatment of warts. J Am Acad Dermatol 1995;32:436-441
21. Lipke MM. An armamentarium of wart treatments. Review. Clin Med Res 2006;4(4):273-293 (Pubitemid 46170319)
22. Orlando G, Fasolo MM, Beretta R, et al. Combined surgery and cidofovir is an effective treatment for genital warts in HIV infected patients. AIDS 2002;16(3):447-450 (Pubitemid 34165377)
23. Nathan M, Hickey N, Mayuranathan L, et al. Treatment of anal human papillomavirus-associated disease: a long term outcome study. Int J STD AIDS 2008;19(7):445-449
24. Runfola MA, Weber TK, Rodriguez-Bigas MA, et al. Photodynamic therapy for residual neoplasms of the perineal skin. Dis Colon Rectum 2000;43:499-502 (Pubitemid 30225432)
25. Kimberlin DW. Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomavirus. Antiviral Res 2004;63:141-151 (Pubitemid 39286751)
26. Bonnez W, Oakes D, Bailey-Farchione A, et al. A randomized, double-blind, placebo-controlled trial of systemically administered interferon-alpha, -beta or -gamma in combination with cryotherapy of the treatment of condylomata acuminatum. J Infect Dis 1995;171:1081-1089
27. Arrese J, Paquet P, Claessens H, et al. Dermal dendritic cells in anogenital warty lesions unresponsive to an immune-response modifier. J Cutan Pathol 2001;28(3):131-134 (Pubitemid 32112997)
28. Snoeck R, Noel JC, Muller C, et al. Cidofovir, a new approach of the treatment of cervix intraepithelial neoplasia grade III (CINIII). J Med Virol 2000;60:205-209 (Pubitemid 30036799)
29. De Clercq E. Broad-spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkylpurines and pyrimidines. Biochem Pharmacol 1991;42:963-972
30. Cihlár T, Votruba I, Horska K, et al. Metabolism of 1-(s)-(3-hydroxy-2-phosphonomethoxypropyl)-cytosine (HPMPC) in human embryonic lung cells. Collect Czech Chem Commu 1992;57:661-672
31. Ho HT, Woods KL, Bronson JJ, et al. Intracellular metabolism of antiherpes agent (s)-1[3-hydroxy-2(phosphonylthoxy)propyl]cytosine. Mol Pharmacol 1992;41:197-202
32. Cundy KC, Lynch G, Shaw J-P, et al. Biochemical pharmacology of acyclic nucleotide analogue. Ann N Y Acad Sci 1990;616:398-407
33. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003;16:569-596
34. Cundy KC, Lynch G, Shaw J-P, et al. Distribution and metabolism of intravitreal cidofovir and cyclic HPMPC in rabbits. Curr Eye Res 1996;15:569-576 (Pubitemid 26162460)
35. Spanos WC, El-Deiry M, Lee JH. Cidofovir incorporation into human keratinocytes with episomal HPV 16 results in nonselective cytotoxicity. Ann Otol Rhinol Laryngol 2005;111(11):840-846 (Pubitemid 43231937)
36. Andrei G, Snoeck R, Schols D, De Clercq E. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res 2000;12:397-408 (Pubitemid 33781092)
37. Johnson JA, Gangemi JD. Selective inhibition of human papillomavirus-induced cell proliferation by (s)-1[3-hydroxy-2- (phosphonylmethoxy)propyl]cytosine. Antimicrob Agents Chemother 1999;43:1198-1205 (Pubitemid 29214747)
38. De Clercq E, Andrei G, Balzarini J, et al. Antitumor potential of acyclic nucleoside phophonates. Nucleosides Nucleotides 1999;18:759-771 (Pubitemid 29320593)
39. Liekens S, Andrei G, Vandeputte M, et al. Potent inhibition of hemangioma formation in rats by the acyclic nucleoside phosphonate analogue cidofovir. Cancer Res 1998;58(12):2562-2567 (Pubitemid 28275426)
40. Johnson JA, Gangemi JD. Alpha interferon augments cidofovir's antiviral and antiproliferative activities. Antimicrob Agents Chemother 2003;47(6):2022-2026 (Pubitemid 36637838)
41. Cundy KC, Li ZH, Hichcock MJ, Lee WA. Pharmakokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. Drug Metab Dispos 1996;24:738-744
42. Wachsman M, Petty BG, Cundy KC, et al. Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human deficiency virus-infected subjects. Antiviral Res 1996;29:153-161 (Pubitemid 26135174)
43. Wachsman M, Petty B, Jaffe H, et al. Phase I trial of a new anti-cytomegalovirus agent (s)-1-[3-hydroxy-2 (phosphonylmethoxy)-propyl] cytosine (HPMPC) in HIV infected volunteers. Antiviral Res 1994;109(1):93
44. Cundy KC, Lynch G, Lee WA. Bioavailability and metabolism of cidofovir following topical administration to rabbits. Antiviral Res 1997;35:113-122 (Pubitemid 27263345)
45. Cundy KC, Petty BP, Flaherty J, et al. Clinical pharmacokinetics of cidofovir in HIV-infected patients. Antimicrob Agents Chemother 1995;39:1247-1252
46. Aspe E, Guy RH, Lee WA, et al. Optimization of in vitro flux through hairless mouse skin cidofovir, a potent nucleotide analog. J Pharm Sci 1995;84:750-754
47. Okamoto H, Muta K, Hashida M, Sezaki H. Percutaneous penetration of acyclovir through excised mouse & rat skin. Effect of vehicle and percutaneous penetration enhancer. Pharm Res 1990;7:64-68
48. Kern ER, Palmer J, Vogt PE, et al. Efficacy and pharmacokinetics of topical HPMPC in a genital herpes model. Antiviral Res 1995;26:A341
49. Bienvenu B, Martinez F, Devergie A, et al. Topical use of cidofovir induced acute renal failure. Transplantation 2002;73:661-662 (Pubitemid 34193635)
50. Snoeck R, Van Ranst M, Andrei G, et al. Treatment of anogenital papilloma virus infections with an acyclic nucleoside phosphonate analogue (letter). N Engl J Med 1995;333:943-944
51. Martinelli C, Farese A, Del Mistro A, et al. Resolution of recurrent perianal condylomata acuminata by topical cidofovir in patients with HPV infection. JEADV 2001;15:568-569 (Pubitemid 34041192)
52. Stragier I, Snoeck R, De Clercq E, et al. Local treatment of HPV-induced skin lesions by Cidofovir. J Med Virol 2002;67(2):241-245 (Pubitemid 34493438)
53. Bonatti H, Aigner F, De Clercq E, et al. Local administration of cidofovir for human papilloma virus associated skin lesions in transplant recipients. Transpl Int 2007;20:238-246 (Pubitemid 46246541)
54. Coremans G, Wyndaele J, Dockx S, et al. Eradication of intra-anal condylomata acuminata and histologically dysplasia with combined intralaesional cidofovir and coagulations. Gastroenterology 2008;134:A-318(M1009)
55. Hengge UR, Tietze G. Succesful treatment of recalcitrant condyloma with topical cidofovir. Sex Transm Infect 2000;76:143 (Pubitemid 30262259)
56. Schurmann D, Bergmann F, Temmesfeld-Wollbruck B, et al. Topical cidofovir is effective in treating extensive penile condylomata acuminata. AIDS 2000;14:1075-1076 (Pubitemid 30336078)
57. Koonsaeng S, Verschraegen C, Freedman R, et al. Case Report. Succesful treatment of recurrent vulvar intraepithelial neoplasia resistant to interferon and isotretinoin with cidofovir. J Med Vir 2001;64:195-198 (Pubitemid 32405409)
58. Snoeck R, Bossens M, Parent D, et al. Phase II double-blind placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin Infect Dis 2001;33:597-602 (Pubitemid 32762931)
59. Coremans G, Margaritis V, Snoeck R, et al. Topical cidofovir (HPMPC) is an effective adjuvant to surgical treatment of anogenital condylomata acuminata. Dis Colon Rectum 2003;46:1103-1108 (Pubitemid 36992994)
60. Bischofberger N, Hitchcock MJM, Chen MS, et al. Cyclic HPMPC: an intracellular prodrug for HPMPC with improved therapeutic index in vivo. Antimicrob Agents Chemother 1994;38:2387-2391
61. Lalezari JP, Drew WL, Glutzer E, et al. HPMPC: result of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 1995;171:788-796
62. Cundy KC, Li ZH, Lee WA. Effect of concomitant probeneed on the tissue distribution and urinary excretion of HPMPC in preclinical models. Pharm Res 1994;11 (Suppl):S-449
63. Wutzler P, Thust R. Genetic risks of antiviral nucleoside analogues - a survey. Antiviral Res 2001;49(2):55-74 (Pubitemid 32206741)